Three-arm clinical trial of improved flour targeting intestinal microbiota (MALINEA)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Three-arm clinical trial of improved flour targeting intestinal microbiota (MALINEA). / Vray, Muriel; Tondeur, Laura; Hedible, Boris G; Randremanana, Rindra Vatosoa; Manirakiza, Alexandre; Lazoumar, Ramatoulaye Hamidou; Platen, Cassandre Van; Vargas, Antonio; Briend, André; Jambou, Ronan; Malinea Clinical Trial Group.

I: Maternal and Child Nutrition, Bind 20, Nr. 3, e13649, 2024.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Vray, M, Tondeur, L, Hedible, BG, Randremanana, RV, Manirakiza, A, Lazoumar, RH, Platen, CV, Vargas, A, Briend, A, Jambou, R & Malinea Clinical Trial Group 2024, 'Three-arm clinical trial of improved flour targeting intestinal microbiota (MALINEA)', Maternal and Child Nutrition, bind 20, nr. 3, e13649. https://doi.org/10.1111/mcn.13649

APA

Vray, M., Tondeur, L., Hedible, B. G., Randremanana, R. V., Manirakiza, A., Lazoumar, R. H., Platen, C. V., Vargas, A., Briend, A., Jambou, R., & Malinea Clinical Trial Group (2024). Three-arm clinical trial of improved flour targeting intestinal microbiota (MALINEA). Maternal and Child Nutrition, 20(3), [e13649]. https://doi.org/10.1111/mcn.13649

Vancouver

Vray M, Tondeur L, Hedible BG, Randremanana RV, Manirakiza A, Lazoumar RH o.a. Three-arm clinical trial of improved flour targeting intestinal microbiota (MALINEA). Maternal and Child Nutrition. 2024;20(3). e13649. https://doi.org/10.1111/mcn.13649

Author

Vray, Muriel ; Tondeur, Laura ; Hedible, Boris G ; Randremanana, Rindra Vatosoa ; Manirakiza, Alexandre ; Lazoumar, Ramatoulaye Hamidou ; Platen, Cassandre Van ; Vargas, Antonio ; Briend, André ; Jambou, Ronan ; Malinea Clinical Trial Group. / Three-arm clinical trial of improved flour targeting intestinal microbiota (MALINEA). I: Maternal and Child Nutrition. 2024 ; Bind 20, Nr. 3.

Bibtex

@article{6ebb76c04dd34f9394df87ec9dfeaed3,
title = "Three-arm clinical trial of improved flour targeting intestinal microbiota (MALINEA)",
abstract = "The main objective of this project was to compare in the field conditions two strategies of re-nutrition of children with moderate acute malnutrition (MAM) aged from 6 to 24 months, targeting the microbiota in comparison with a standard regimen. A three-arm, open-label, pragmatic randomised trial was conducted in four countries (Niger, CAR, Senegal and Madagascar). Children received for 12 weeks either fortified blended flour (FBF control) = arm 1, or FBF + azithromycin (oral suspension of 20 mg/kg/day daily given with a syringe) for the first 3 days at inclusion = arm 2 or mix FBF with inulin/fructo-oligosaccharides (6 g/day if age ≥12 months and 4 g if age <12 months) = arm 3. For each arm, children aged from 6 to 11 months received 100 g x 2 per day of flours and those aged from 12 to 24 months received 100 g × 3 per day of FBF. The primary endpoint was nutritional recovery, defined by reaching a weight-for-height z-score (WHZ) ≥ -1.5 within 12 weeks. Overall, 881 children were randomised (297, 290 and 294 in arm 1, arm 2 and arm 3, respectively). Three hundred and forty-four children were males (39%) and median/mean age were 14.6/14.4 months (SD = 4.9, IQR = 10.5-18.4). At inclusion, the three arms were comparable for all criteria, but differences were observed between countries. Overall, 44% (390/881) of the children recovered at week 12 from MAM, with no significant difference between the three arms (41.4%, 45.5% and 45.9%, in arm 1, arm 2 and arm 3, respectively, p = 0.47). This study did not support the true advantages of adding a prebiotic or antibiotic to flour. When using a threshold of WHZ ≥ -2 as an exploratory endpoint, significant differences were observed between the three arms, with higher success rates in arms with antibiotics or prebiotics compared to the control arm (66.9%, 66.0% and 55.2%, respectively, p = 0.005).",
author = "Muriel Vray and Laura Tondeur and Hedible, {Boris G} and Randremanana, {Rindra Vatosoa} and Alexandre Manirakiza and Lazoumar, {Ramatoulaye Hamidou} and Platen, {Cassandre Van} and Antonio Vargas and Andr{\'e} Briend and Ronan Jambou and {Malinea Clinical Trial Group}",
note = "{\textcopyright} 2024 The Authors. Maternal & Child Nutrition published by John Wiley & Sons Ltd.",
year = "2024",
doi = "10.1111/mcn.13649",
language = "English",
volume = "20",
journal = "Maternal and Child Nutrition",
issn = "1740-8695",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Three-arm clinical trial of improved flour targeting intestinal microbiota (MALINEA)

AU - Vray, Muriel

AU - Tondeur, Laura

AU - Hedible, Boris G

AU - Randremanana, Rindra Vatosoa

AU - Manirakiza, Alexandre

AU - Lazoumar, Ramatoulaye Hamidou

AU - Platen, Cassandre Van

AU - Vargas, Antonio

AU - Briend, André

AU - Jambou, Ronan

AU - Malinea Clinical Trial Group

N1 - © 2024 The Authors. Maternal & Child Nutrition published by John Wiley & Sons Ltd.

PY - 2024

Y1 - 2024

N2 - The main objective of this project was to compare in the field conditions two strategies of re-nutrition of children with moderate acute malnutrition (MAM) aged from 6 to 24 months, targeting the microbiota in comparison with a standard regimen. A three-arm, open-label, pragmatic randomised trial was conducted in four countries (Niger, CAR, Senegal and Madagascar). Children received for 12 weeks either fortified blended flour (FBF control) = arm 1, or FBF + azithromycin (oral suspension of 20 mg/kg/day daily given with a syringe) for the first 3 days at inclusion = arm 2 or mix FBF with inulin/fructo-oligosaccharides (6 g/day if age ≥12 months and 4 g if age <12 months) = arm 3. For each arm, children aged from 6 to 11 months received 100 g x 2 per day of flours and those aged from 12 to 24 months received 100 g × 3 per day of FBF. The primary endpoint was nutritional recovery, defined by reaching a weight-for-height z-score (WHZ) ≥ -1.5 within 12 weeks. Overall, 881 children were randomised (297, 290 and 294 in arm 1, arm 2 and arm 3, respectively). Three hundred and forty-four children were males (39%) and median/mean age were 14.6/14.4 months (SD = 4.9, IQR = 10.5-18.4). At inclusion, the three arms were comparable for all criteria, but differences were observed between countries. Overall, 44% (390/881) of the children recovered at week 12 from MAM, with no significant difference between the three arms (41.4%, 45.5% and 45.9%, in arm 1, arm 2 and arm 3, respectively, p = 0.47). This study did not support the true advantages of adding a prebiotic or antibiotic to flour. When using a threshold of WHZ ≥ -2 as an exploratory endpoint, significant differences were observed between the three arms, with higher success rates in arms with antibiotics or prebiotics compared to the control arm (66.9%, 66.0% and 55.2%, respectively, p = 0.005).

AB - The main objective of this project was to compare in the field conditions two strategies of re-nutrition of children with moderate acute malnutrition (MAM) aged from 6 to 24 months, targeting the microbiota in comparison with a standard regimen. A three-arm, open-label, pragmatic randomised trial was conducted in four countries (Niger, CAR, Senegal and Madagascar). Children received for 12 weeks either fortified blended flour (FBF control) = arm 1, or FBF + azithromycin (oral suspension of 20 mg/kg/day daily given with a syringe) for the first 3 days at inclusion = arm 2 or mix FBF with inulin/fructo-oligosaccharides (6 g/day if age ≥12 months and 4 g if age <12 months) = arm 3. For each arm, children aged from 6 to 11 months received 100 g x 2 per day of flours and those aged from 12 to 24 months received 100 g × 3 per day of FBF. The primary endpoint was nutritional recovery, defined by reaching a weight-for-height z-score (WHZ) ≥ -1.5 within 12 weeks. Overall, 881 children were randomised (297, 290 and 294 in arm 1, arm 2 and arm 3, respectively). Three hundred and forty-four children were males (39%) and median/mean age were 14.6/14.4 months (SD = 4.9, IQR = 10.5-18.4). At inclusion, the three arms were comparable for all criteria, but differences were observed between countries. Overall, 44% (390/881) of the children recovered at week 12 from MAM, with no significant difference between the three arms (41.4%, 45.5% and 45.9%, in arm 1, arm 2 and arm 3, respectively, p = 0.47). This study did not support the true advantages of adding a prebiotic or antibiotic to flour. When using a threshold of WHZ ≥ -2 as an exploratory endpoint, significant differences were observed between the three arms, with higher success rates in arms with antibiotics or prebiotics compared to the control arm (66.9%, 66.0% and 55.2%, respectively, p = 0.005).

U2 - 10.1111/mcn.13649

DO - 10.1111/mcn.13649

M3 - Journal article

C2 - 38599819

VL - 20

JO - Maternal and Child Nutrition

JF - Maternal and Child Nutrition

SN - 1740-8695

IS - 3

M1 - e13649

ER -

ID: 389089068